) The University of Colorado Comprehensive Cancer Center (UCCC) is the only NCI- designed comprehensive Cancer Center in the Rocky Mountain region which has a population of about 8 million. The goals are to: 1) contribute to the reduction and elimination of cancer as a human health problem through coordinated programs in basic, clinical, translational and population sciences and 2) provide the citizens of the Rocky Mountain region with state-of-the-art cancer research, clinical, prevention and control and education programs. There are 244 full and 82 associate members who participate in one or more of the UCCC's 10 program including Cell Biology, Molecular and Structural Biology, Immunology and Immunotherapy, Hormone Related Malignancies, Tobacco Related Malignancies, Developmental Therapeutics, Pediatric Oncology, Cancer Genetics, Carcinogenesis and Chemoprevention and Clinical and Community Cancer Prevention and Control. Over the past 5 years, programs were reorganized to foster collaborative and translational research by including elements of basic, clinical and population sciences into the programs and to respond to rapid changes in scientific technology. UCCC members' productivity has increased as documented by more grant funding (32%), by a phenomenal growth in accruals to clinical trials (>1000%) and by their publication record. Cancer focus also increased as shown by the increases in NCI and peer-reviewed cancer agency funding (36%), and the increase in cancer clinical trials noted above. The research of the members is supported by 15 shared core resources which include 4 new facilities (Gene Expression, NMR, Pharmacology, Survey Research), 9 cores with expanded services (Biostatistics, Clinical Investigations, Cytogenetics, Flow Cytometry, Laboratory Animals, Tissue Procurement, Radiological Sciences, Protein Microchemistry, and Transgenic/Knockout) and 2 cores with continued services utilized by increased number of members (DNA Sequencing and Tissue Culture/Monoclonal Antibody). Core usage has increased over the past 5 years as documented by number of members, units of use, and charge back fees generated (110% increase). We have emphasized new technologies in the creation and expansion of these services. The UCCC is a """"""""matrix"""""""" Center within the School of Medicine, but has members from all of the UCHSC schools and affiliated institutions. During the next 3 years the UCCC will relocate to the new Fitzsimons campus which will triple the available outpatient and clinical research space (Nov. 2000) and the basic research space (Nov. 2002) at a cost of more than $180 million.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-18
Application #
6855221
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1988-03-01
Project End
2006-01-31
Budget Start
2005-05-19
Budget End
2006-01-31
Support Year
18
Fiscal Year
2005
Total Cost
$3,562,737
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Witt, Davis A; Donson, Andrew M; Amani, Vladimir et al. (2018) Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy. Pediatr Blood Cancer 65:e26960
McCoach, Caroline E; Le, Anh T; Gowan, Katherine et al. (2018) Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res 24:3334-3347
Abraham, Christopher G; Ludwig, Michael P; Andrysik, Zdenek et al. (2018) ?Np63? Suppresses TGFB2 Expression and RHOA Activity to Drive Cell Proliferation in Squamous Cell Carcinomas. Cell Rep 24:3224-3236
Sanchez, Gilson J; Richmond, Phillip A; Bunker, Eric N et al. (2018) Genome-wide dose-dependent inhibition of histone deacetylases studies reveal their roles in enhancer remodeling and suppression of oncogenic super-enhancers. Nucleic Acids Res 46:1756-1776
Noonan, Sinead A; Patil, Tejas; Gao, Dexiang et al. (2018) Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. J Thorac Oncol 13:134-138
Guarnieri, A L; Towers, C G; Drasin, D J et al. (2018) The miR-106b-25 cluster mediates breast tumor initiation through activation of NOTCH1 via direct repression of NEDD4L. Oncogene 37:3879-3893
Davies, Kurtis D; Le, Anh T; Sheren, Jamie et al. (2018) Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples. J Thorac Oncol 13:1474-1482
Lyu, Hui; Wang, Shuiliang; Huang, Jingcao et al. (2018) Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer. Cancer Lett 420:97-108
Lee-Sherick, Alisa B; Jacobsen, Kristen M; Henry, Curtis J et al. (2018) MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity. JCI Insight 3:
Drilon, Alexander; Laetsch, Theodore W; Kummar, Shivaani et al. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378:731-739

Showing the most recent 10 out of 1634 publications